ΑΛΕΞΑΝΔΡΟΣ ΖΗΣΟΠΟΥΛΟΣ - ΟΥΡΟΛΟΓΟΣ
  • Αρχικη
  • ΙΑΤΡΟΣ
    • ΒΙΟΓΡΑΦΙΚΟ
    • ΔΗΜΟΣΙΕΥΣΕΙΣ
    • ΙΑΤΡΕΙΟ
    • ΕΞΟΠΛΙΣΜΟΣ
  • ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ
    • ΣΥΜΠΤΩΜΑΤΑ
    • ΕΞΕΤΑΣΕΙΣ
    • ΠΑΘΗΣΕΙΣ >
      • ΟΓΚΟΛΟΓΙΑ >
        • ΚΑΡΚΙΝΟΣ ΚΥΣΤΗΣ
        • ΚΑΡΚΙΝΟΣ ΝΕΦΡΟΥ
        • ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ
        • ΚΑΡΚΙΝΟΣ ΠΕΟΥΣ
        • ΚΑΡΚΙΝΟΣ ΠΡΟΣΤΑΤΗ
      • ΠΑΘΗΣΕΙΣ ΠΡΟΣΤΑΤΗ >
        • ΥΠΕΡΠΛΑΣΙΑ ΠΡΟΣΤΑΤΗ
        • ΚΑΡΚΙΝΟΣ ΠΡΟΣΤΑΤΗ
        • ΠΡΟΣΤΑΤΙΤΙΔΑ
      • ΑΝΔΡΟΛΟΓΙΑ >
        • ΚΙΡΣΟΚΗΛΗ
        • ΚΟΝΔΥΛΩΜΑΤΑ
        • ΠΡΟΩΡΗ ΕΚΣΠΕΡΜΑΤΙΣΗ
        • ΣΤΥΤΙΚΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ
        • ΣΥΣΤΡΟΦΗ ΟΡΧΕΩΣ
        • ΥΔΡΟΚΗΛΗ
        • ΦΙΜΩΣΗ
      • ΑΚΡΑΤΕΙΑ ΟΥΡΩΝ
      • ΟΥΡΟΛΟΙΜΩΞΕΙΣ
      • ΚΥΣΤΕΙΣ ΝΕΦΡΩΝ
      • ΛΙΘΙΑΣΗ ΟΥΡΟΠΟΙΗΤΙΚΟΥ
    • ΕΠΕΜΒΑΣΕΙΣ
    • ΣΥΧΝΕΣ ΕΡΩΤΗΣΕΙΣ
  • INFOGRAPHICS
  • TEST
  • ΕΠΙΚΟΙΝΩΝΙΑ
  • ΝΕΑ

Prostate Cancer Radiotherapy Outcomes Worse in Smokers

11/11/2014

0 Comments

 
Picture
Prostate cancer (PCa) patients who smoke while undergoing external beam radiotherapy (EBRT) are at significantly increased risk of dying from their cancer compared with their never-smoking counterparts, according to a new study.

Michael J. Zelefsky, MD, and colleagues in the Department of Radiation Oncology at Memorial Sloan-Kettering Center in New York analyzed data from 2,156 PCa patients receiving EBRT and who had smoking histories recorded in their medical charts. The investigators classified patients as never smokers, current smokers, former smokers, and current smoking unknown. The median follow-up was 95 months.

Compared with never smoking, current smoking was associated with a significant 40% increased risk of PSA relapse, 2.4 times increased risk of developing distant metastases, and a 2.2 times increased risk of PCa-specific death, Dr. Zelefsky's group reported online ahead of print in BJU International. In addition, current and former smokers had a significant 80% and 45% increased risk of EBRT-related genitourinary toxicities, respectively.

“Given the increased risk of prostate cancer progression and radiation toxicity among smokers, a stronger emphasis on smoking cessation is clearly appropriate,” the authors wrote. “With a growing number of cancer survivors nationwide, there is a concomitant increase in attention to behavior medication among survivors.”

Dr. Zelefsky's team cited research findings showing that upwards of 50% of smokers with cancer continue to smoke after their diagnosis, and PSA relapse rates are higher among those who do not quit. They also noted that among those who continue to smoke during radiotherapy the urinary side effects can be accentuated.

Previous studies have found an association between long-term smoking and systemic hypoxia, and hypoxia at the radiotherapy target site is known to decrease treatment efficacy. Although this association has been better studied in head and neck cancers, Dr. Zelefsky and his colleagues noted, the principle may be applicable to PCa as well and could explain the worse prognosis observed among smokers.

For the study, Dr. Zelefsky's team defined current smokers as those who were smoking at the time of the initial consultation and the initiation of EBRT. They defined former smokers as men who had quit smoking before starting EBRT, even if this cessation occurred several weeks or years before treatment.

0 Comments



Leave a Reply.

    Σχετικά

    Με το ιστολόγιο αυτό επιχειρείται η κατά το δυνατόν άμεση ενημέρωση σε θέματα που αφορούν ουρολογικές εξελίξεις και δίνεται η δυνατότητα σχολιασμού των αναρτήσεων.

    RSS Feed

    Κατηγορίες

    All
    Benign Prostatic Hyperplasia
    Bladder Cancer
    EAU NEWS
    EAU Video News
    Erectile Dysfunction
    EUT Congress News
    Hypogonadism
    Interstitial Cystitis
    Kidney Cancer
    Kidney Stones
    Overactive Bladder
    Pelvic Pain
    Premature Ejaculation
    Prostate Cancer
    Prostate Specific Antigen
    Reproductive Medicine
    Testicular Cancer
    Urinary Incontinence
    Urinary Tract Infections
    Various

Ιατρείο Θεσσαλονίκης: Εθνικής Αντιστάσεως 74, Καλαμαριά
​Τ: 2310 44 44 62, Κ: 693 63 23 794
Ιατρείο Λαγκαδά: Δ. Μήλιου 24 (έναντι 1ου δημοτικού), Λαγκαδάς 
Τ: 2394 020 780, Κ: 693 63 23 794
Όροι Χρήσης | Επικοινωνία | Copyright © 2013
  • Αρχικη
  • ΙΑΤΡΟΣ
    • ΒΙΟΓΡΑΦΙΚΟ
    • ΔΗΜΟΣΙΕΥΣΕΙΣ
    • ΙΑΤΡΕΙΟ
    • ΕΞΟΠΛΙΣΜΟΣ
  • ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ
    • ΣΥΜΠΤΩΜΑΤΑ
    • ΕΞΕΤΑΣΕΙΣ
    • ΠΑΘΗΣΕΙΣ >
      • ΟΓΚΟΛΟΓΙΑ >
        • ΚΑΡΚΙΝΟΣ ΚΥΣΤΗΣ
        • ΚΑΡΚΙΝΟΣ ΝΕΦΡΟΥ
        • ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ
        • ΚΑΡΚΙΝΟΣ ΠΕΟΥΣ
        • ΚΑΡΚΙΝΟΣ ΠΡΟΣΤΑΤΗ
      • ΠΑΘΗΣΕΙΣ ΠΡΟΣΤΑΤΗ >
        • ΥΠΕΡΠΛΑΣΙΑ ΠΡΟΣΤΑΤΗ
        • ΚΑΡΚΙΝΟΣ ΠΡΟΣΤΑΤΗ
        • ΠΡΟΣΤΑΤΙΤΙΔΑ
      • ΑΝΔΡΟΛΟΓΙΑ >
        • ΚΙΡΣΟΚΗΛΗ
        • ΚΟΝΔΥΛΩΜΑΤΑ
        • ΠΡΟΩΡΗ ΕΚΣΠΕΡΜΑΤΙΣΗ
        • ΣΤΥΤΙΚΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ
        • ΣΥΣΤΡΟΦΗ ΟΡΧΕΩΣ
        • ΥΔΡΟΚΗΛΗ
        • ΦΙΜΩΣΗ
      • ΑΚΡΑΤΕΙΑ ΟΥΡΩΝ
      • ΟΥΡΟΛΟΙΜΩΞΕΙΣ
      • ΚΥΣΤΕΙΣ ΝΕΦΡΩΝ
      • ΛΙΘΙΑΣΗ ΟΥΡΟΠΟΙΗΤΙΚΟΥ
    • ΕΠΕΜΒΑΣΕΙΣ
    • ΣΥΧΝΕΣ ΕΡΩΤΗΣΕΙΣ
  • INFOGRAPHICS
  • TEST
  • ΕΠΙΚΟΙΝΩΝΙΑ
  • ΝΕΑ